Laleh Amiri‐Kordestani
0000-0002-0056-5437
Publication & Citation Trends
Publications
0 total
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle Invasive Bladder Cancer.
Cited by 0
Semantic Scholar
Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?
Cited by 0
Semantic Scholar
Abstract PS1-10-13: Fulvestrant Post-CDK Inhibitor in Hormone Receptor-Positive Breast Cancer: A Pooled FDA Analysis
Cited by 0
Semantic Scholar
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Cited by 9
Semantic Scholar
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.
Cited by 0
Semantic Scholar
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.
Cited by 2
Semantic Scholar
Overall survival in patients with HR+/HER2- advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus an aromatase inhibitor: A US Food and Drug Administration pooled analysis.
Cited by 0
Semantic Scholar
Research Topics
Advanced Breast Cancer Therapies
(48)
Cancer Immunotherapy and Biomarkers
(39)
Cancer Treatment and Pharmacology
(35)
Cancer Genomics and Diagnostics
(32)
Renal cell carcinoma treatment
(30)
Affiliations
Leidos (United States)
Roche (Switzerland)
Novartis (Switzerland)
National Institutes of Health
United States Food and Drug Administration